Antibiotics - The Perfect Storm

We need new antibiotics to fight infections caused by resistant bacteria. But the marketplace, the structure of the pharmaceutical industry, regulatory agencies, and difficult science are conspiring to deny us the products we need. This blog will present perspectives and developments in the fight for new antibiotics.

Monday, December 13, 2021

Covid - Thank you to industry - Please do the same for AMR.

›
  To all those who are skeptical because they worry that a government sponsored investment in the broken antibiotic marketplace is a give-aw...
Thursday, December 2, 2021

Pull Incentives for AMR - Where is Biden?

›
 This will be a short note . . . We are about to dedicate an entire  ASM/ESCMID  session to planning for the implementation of forthcoming p...
Monday, November 22, 2021

Pull Incentives at ASM/ESCMID

›
  On a personal note, as I grow older, I find I am likely to be more dependent on physicians and caregivers.  I am grateful to have a truly ...
Monday, October 11, 2021

Europe, Antibacterials, Pull Incentives and Access

›
      Without a significant pull incentive, our pipeline of new antibacterials is doomed. This must be our top priority. If a significant pu...
Tuesday, October 5, 2021

Empiric broad spectrum antimicrobial therapy is here to stay.

›
  Recent discussions on the economics of innovation in rapid diagnostic testing for bacterial infections in the hospital setting have inspir...
Monday, April 26, 2021

Antibiotic Strategies for Success - A Bridge to Nowhere?

›
  This blog was inspired by a recent conversation with a CEO of a clinical phase antibiotic biotech. Among other things, we pursued a discus...
2 comments:
Monday, April 5, 2021

Pull American - Why Not?

›
  In a sleepy moment I had an inspiration. Funding a pull incentive for antibiotic R&D in the US (like a market entry reward for example...
1 comment:
‹
›
Home
View web version
Powered by Blogger.